Literature DB >> 30474461

Predictors of presarcopenia in community-dwelling older adults: A 5-year longitudinal study.

Kazuyoshi Kobayashi1, Kei Ando1, Mikito Tsushima1, Masaaki Machino1, Kyotaro Ota1, Masayoshi Morozumi1, Satoshi Tanaka1, Shunsuke Kanbara1, Naoki Ishiguro1, Yukiharu Hasegawa2, Shiro Imagama1.   

Abstract

Objectives: Sarcopenia is an aging-induced decrease in muscle mass that increases frailty and fall in elderly people. Presarcopenia corresponds to the preliminary stage of sarcopenia. The purpose of this prospective study is to examine predictors of presarcopenia in health screening.
Methods: The subjects were 124 community residents aged ≥60 years (55 males, 69 females, average age 70.2 years) who attended local government health checkups in 2010 and 2015, as part of the Yakumo study, and did not have presarcopenia in 2010. Body mass index (BMI), waist and hip circumferences, grip strength, bone mineral density (BMD), 10-m gait time, back muscle strength, and stride length were measured. Presarcopenia was defined using the appendicular skeletal muscle index (arm and leg skeletal muscle mass/height2).
Results: The prevalences of presarcopenia in 2015 in males and females were 21.8% (12/55) and 30.4% (21/69), respectively. BMI, grip strength, BMD, back muscle strength, and osteoporosis deteriorated significantly more in the pre-sarcopenia group (n = 33) compared with controls (n = 91; no presarcopenia in 2015). In multivariate analysis, osteoporosis (OR 3.12, 95% CI 1.07-9.09; p < .05) was significantly associated with presarcopenia after 5 years.Conclusions: Establishment of risk factors for future pre-sarcopenia may allow development of evidence-based prevention strategies for this condition.

Entities:  

Keywords:  Bioelectrical impedance analysis; bone mineral density; osteoporosis; presarcopenia; skeletal muscle mass

Mesh:

Year:  2019        PMID: 30474461     DOI: 10.1080/14397595.2018.1551171

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  Presarcopenia in Patients with Vitiligo: A Case Control Study.

Authors:  Faiq I Gorial; Sarah Khalaf Jehad; Salwa Faris Taha; Aseen Adil Tawfeeq
Journal:  Mediterr J Rheumatol       Date:  2021-05-28

2.  Locomotive Syndrome Stage 1 Predicts Significant Worsening of Future Motor Performance: The Prospective Yakumo Study.

Authors:  Kazuyoshi Kobayashi; Shiro Imagama; Kei Ando; Masaaki Machino; Satoshi Tanaka; Masayoshi Morozumi; Shunsuke Kanbara; Sadayuki Ito; Taro Inoue; Naoki Ishiguro; Yukiharu Hasegawa
Journal:  Biomed Res Int       Date:  2019-10-03       Impact factor: 3.411

3.  Besides Sarcopenia, Pre-Sarcopenia Also Predicts All-Cause Mortality in Older Chileans.

Authors:  Lydia Lera; Bárbara Angel; Carlos Marquez; Rodrigo Saguez; Cecilia Albala
Journal:  Clin Interv Aging       Date:  2021-04-15       Impact factor: 4.458

4.  Bioelectrical Impedance Analysis and Manual Measurements of Neck Circumference Are Interchangeable, and Declining Neck Circumference Is Related to Presarcopenia.

Authors:  Masaaki Machino; Kei Ando; Kazuyoshi Kobayashi; Hiroaki Nakashima; Satoshi Tanaka; Shunsuke Kanbara; Sadayuki Ito; Taro Inoue; Hiroyuki Koshimizu; Taisuke Seki; Shinya Ishizuka; Yasuhiko Takegami; Yukiharu Hasegawa; Shiro Imagama
Journal:  Biomed Res Int       Date:  2021-03-29       Impact factor: 3.411

5.  Relationship of frequency of participation in a physical checkup and physical fitness in middle-aged and elderly people: the Yakumo study.

Authors:  Kazuyoshi Kobayashi; Kei Ando; Hiroaki Nakashima; Masaaki Machino; Shunsuke Kanbara; Sadayuki Ito; Taro Inoue; Hidetoshi Yamaguchi; Hiroyuki Koshimizu; Naoki Segi; Yukiharu Hasegawa; Shiro Imagama
Journal:  Nagoya J Med Sci       Date:  2021-11       Impact factor: 1.131

6.  An association analysis between hypertension, dementia, and depression and the phases of pre-sarcopenia to sarcopenia: A cross-sectional analysis.

Authors:  Takeshi Endo; Kenju Akai; Tsunetaka Kijima; Shigetaka Kitahara; Takafumi Abe; Miwako Takeda; Toru Nabika; Shozo Yano; Minoru Isomura
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.